INSTANT STREAMING COURSE
Share:

The Art Of Technology Transfer In Drug Development: Developing And Building A Framework Of Success

This course builds practical capability to structure repeatable technology transfer activities across pharmaceutical development using risk assessment, knowledge management, and process understanding. Participants will strengthen internal decision-making by connecting QTPP, CQAs, control strategy, and transfer planning into a coordinated operational approach. This Course is designed for professionals involved in pharmaceutical development, process transfer, quality systems, and technical operations oversight.

REGISTER FOR THE COURSE

US $190 per learner

30-Days Unlimited Streaming Access

/* Hide default + / - icon */ .accordion-toggle-icon { opacity: 0; } /* Add circle instead */ .accordion-header::after { content: "○"; font-size: 18px; margin-left: auto; transition: 0.2s ease; } /* When open → filled circle */ .accordion-item.active .accordion-header::after { content: "●"; } /* Hide default + / - icon */ .accordion-toggle-icon { opacity: 0; } /* Add circle instead */ .accordion-header::after { content: "○"; font-size: 18px; margin-left: auto; transition: 0.2s ease; } /* When open → filled circle */ .accordion-item.active .accordion-header::after { content: "●"; } .accordion-header::after { content: "◯"; font-size: 18px; transition: transform 0.25s ease; } .accordion-item.active .accordion-header::after { transform: rotate(90deg); }

REGISTER FOR THE COURSE

To Get 30-Day Access to ONLY this Course 

US $190 per learner
  • This course is Included in Subscription Pack
Subscription include access to entire Learning Library
/* Hide default + / - icon */ .accordion-toggle-icon { opacity: 0; } /* Add circle instead */ .accordion-header::after { content: "○"; font-size: 18px; margin-left: auto; transition: 0.2s ease; } /* When open → filled circle */ .accordion-item.active .accordion-header::after { content: "●"; } /* Hide default + / - icon */ .accordion-toggle-icon { opacity: 0; } /* Add circle instead */ .accordion-header::after { content: "○"; font-size: 18px; margin-left: auto; transition: 0.2s ease; } /* When open → filled circle */ .accordion-item.active .accordion-header::after { content: "●"; } .accordion-header::after { content: "◯"; font-size: 18px; transition: transform 0.25s ease; } .accordion-item.active .accordion-header::after { transform: rotate(90deg); }
  • Faculty
    Scott R. Thatcher
  • Duration
    90 Minutes
  • Course ID
    TF2177
  • Ask the Expert
    Included
  • Presentation Handout
    & Templates
  • Assessment
    & Certification Included

About the Course

Technology transfer remains one of the most critical and inconsistently executed activities in pharmaceutical and biopharmaceutical development. In global development environments, organizations depend on repeatable transfer practices to maintain continuity between development, manufacturing, quality, and regulatory expectations. Because formal regulatory direction on technology transfer remains limited, companies must establish internal processes capable of preserving product and process knowledge throughout development activities.


This course addresses the operational and scientific elements required to support successful transfer execution across drug development programs. The material connects pharmaceutical development activities with QTPP, Critical Quality Attributes, risk assessment, control strategy, Quality by Design, materials, methods, and process considerations. Additional focus is placed on knowledge management practices, data systems, pre-transfer gap analysis, protocol development, reporting structure, and project planning. The session also examines critical success factors that influence long-term consistency and transfer reliability across organizations.

  • Strengthen Technology Transfer Decision-Making:

    Participants will gain a structured approach for connecting development knowledge with transfer execution activities across pharmaceutical programs. The course clarifies how QTPP, CQAs, risk assessment, and control strategy contribute to transfer readiness, helping teams reduce operational gaps, improve internal coordination, and support consistency when transferring products, processes, methods, and associated documentation.

  • Build a Repeatable Internal Transfer Process:

    Organizations operating across global development environments often face variability in transfer execution due to limited regulatory direction. This course provides practical perspective on creating transfer frameworks supported by project plans, protocols, reporting practices, knowledge management, and data systems. Participants will better recognize critical concepts that influence transfer continuity, process understanding, and long-term operational reliability.

Key Areas Covered

  • Technology transfer perspective, definitions, and critical success factors across pharmaceutical development activities
  • QTPP, Critical Quality Attributes (CQAs), and Quality by Design (QbD) considerations supporting transfer readiness
  • Risk assessment approaches and pre-transfer gap analysis for process and knowledge evaluation
  • Materials, components, manufacturing processes, analytical methods, and associated development considerations
  • Knowledge management practices, critical concepts, and data systems supporting transfer continuity
  • Technology transfer framework development including project plans, protocols, reports, references, and process execution

Who Must Attend

  • Leadership/Managers
  • Analytical Scientists
  • Formulations Scientists
  • Regulatory Scientists
  • Quality Assurance Departments
  • Document Control Specialists
  • Information Technology Departments
  • Engineering Departments

Quality training, expert insights, and answers that matter. Know your Expert

SCOTT R. THATCHER

Scott Thatcher is a 20+ year veteran of the pharma and biopharma industry with experience supporting CMC development and commercial launch activities across multiple drug programs and delivery systems. His background includes analytical chemistry, photostability studies, stress testing, and analytical method development and validation. He has contributed to regulatory submissions aligned with ICH Q1B expectations and has worked extensively with scientific data and development information critical to

If you would like to request a Proforma invoice to sign up for this course. please click here

Commonly Asked Questions About This Subject

The following questions address practical regulatory, compliance, validation, quality, operational, and inspection-related considerations commonly associated with this subject.

How can organizations demonstrate that critical process knowledge has been successfully transferred rather than simply documented?

Successful technology transfer is demonstrated through consistent execution at the receiving site, not by the volume of documentation produced. Inspectors and auditors look for evidence that technical knowledge was understood, applied, and verified during routine operations rather than merely archived in transfer records.


Supporting evidence often extends beyond the transfer package itself. Manufacturing performance, deviation trends, process investigations, validation outcomes, and operator performance frequently reveal whether important process knowledge was communicated effectively. Repeated clarification requests or recurring operational issues may indicate that essential information was transferred incompletely.


Documentation should also explain why specific process parameters, operating ranges, material controls, and monitoring activities were established. Technical decisions that cannot be linked to documented development knowledge become increasingly difficult to defend when process performance changes after transfer.


A well supported transfer demonstrates continuity between development knowledge and commercial execution. Consistent manufacturing results supported by traceable technical rationale provide stronger evidence than transfer documents that simply confirm required records were completed.

When should unresolved technical uncertainties delay a technology transfer rather than being managed after implementation?

Some uncertainties can be managed through planned monitoring after transfer, while others should be resolved before manufacturing responsibility changes. The deciding factor is whether the remaining uncertainty could significantly affect product quality, process consistency, patient safety, or regulatory commitments.


Supporting evaluations should distinguish between known risks that have documented controls and knowledge gaps that could prevent reliable execution at the receiving site. Assumptions without supporting experimental data or operational evidence often become difficult to defend during inspections or subsequent investigations.


Reviewers also examine whether unresolved issues could affect validation activities, analytical methods, raw material performance, equipment suitability, or critical manufacturing decisions. Deferring these uncertainties without documented justification frequently leads to additional studies, process interruptions, or repeated deviations after transfer.


A documented decision to delay or proceed should explain the technical basis, residual risks, planned monitoring activities, and approval rationale. Records demonstrating deliberate evaluation carry greater credibility than decisions driven primarily by project timelines.

How do inspectors distinguish between isolated transfer issues and evidence of weaknesses in the overall technology transfer process?

Inspectors rarely judge a technology transfer by reviewing a single project. They evaluate whether similar issues appear across multiple transfers, manufacturing sites, products, or development programs, indicating broader weaknesses in organizational knowledge management and governance.


Recurring deviations, repeated protocol revisions, inconsistent manufacturing outcomes, delayed investigations, or frequent post transfer process adjustments often suggest that transfer activities are not consistently preserving critical process knowledge. These patterns usually receive greater attention than isolated execution errors.


Inspection teams commonly compare transfer documentation with validation records, change controls, CAPAs, process performance trends, and quality investigations. Similar deficiencies appearing across several quality systems may indicate that transfer decisions are being made without adequate technical oversight.


Confidence increases when previous transfer experience leads to documented procedural improvements and measurable reductions in recurring issues. Evidence showing that lessons learned were incorporated into subsequent transfers demonstrates that the transfer process remains under effective organizational control.

How should conflicting technical recommendations from development and manufacturing teams be resolved during technology transfer?

Conflicting recommendations should be resolved through documented scientific evaluation rather than organizational authority or project deadlines. Inspectors expect the final decision to reflect objective technical evidence and an understanding of how the proposed approach will affect routine manufacturing performance.


The evaluation should compare supporting development data, manufacturing experience, validation findings, process capability, material performance, and quality risks associated with each option. Decisions based primarily on convenience or historical preference are considerably more difficult to justify during regulatory review.


Review records should clearly identify the differing technical positions, the evidence considered, the rationale for the selected approach, and the approval process used to reach consensus. Transparent documentation demonstrates that competing viewpoints received appropriate technical consideration.


A defensible resolution preserves the scientific basis for future decisions. When subsequent investigations, process improvements, or regulatory questions arise, documented reasoning provides a stronger foundation than relying on institutional knowledge or verbal agreements that cannot be independently verified.

Ready to Strengthen Your Team? Let’s Build Your Training Plan.

Whether you’re looking for a single onsite workshop or a multi-team training series, we’ll help you design a program that fits your goals, timelines, and operational reality.

Your team deserves the clarity.
Your organization deserves the confidence.

Upcoming Courses

Your TalkFDA Webinar Experience

When you reserve your seat, everything is organized for you — from access to certification from one place.

1. Confirmation

You receive a confirmation email and your course appears instantly in your TalkFDA dashboard.

2. Your Course Hub
Your TalkFDA course page becomes your central hub where you can watch the course, access materials, and manage your learning.

3. Access course materials
The presentation handout and other materials can be downloaded inside the Course Player. You could use Discussion feature there to ask your questions.

4. Watch The Streaming and Complete your Course
The course playback will be available on the same course page. You could pause and continue or you can revisit important sections.
5. Earn Your Certificate
Complete the course and your certificate is unlocked automatically in your learning history.

The challenge with training is rarely signing up. It’s what happens afterward, when access, materials, & certification aren’t accessible from one place.
With TalkFDA Courses, Everything you need Live in One Place.
Simple. Organized. Professional.
Go ahead and Take the Course with confidence.

Our students love us ❤️

Good balance. Not too basic, not too deep. Worked well for mixed team.”


Manager, Regulatory Affairs

“Presenter handled questions well. Didn’t avoid anything.”



Consultant, Compliance

“Would consider similar sessions again. Format worked for us.”



Director, Regulatory Affairs

People who took this Course, also viewed